Steven Valiquette

Q: What is Steven Valiquette's success rate?

Steven Valiquette currently has a success rate of 93.43763534306532.

Q: What is the average return of Steven Valiquette's calls?

Their stock ratings have generated an average return of 17.80114987598899.

Mizuho | Healthcare

Steven Valiquette is an analyst from Mizuho specializing in the Healthcare sector. Ranked #1500 out of 4773 analysts, they have issued 30 stock ratings with a success rate of 93.44% and an average return of 17.80%.

Steven Valiquette has a well-established track record, with 30 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 93.44% and an average return of 17.80%, underscoring their expertise and ability to identify winning opportunities for investors.

#1500

Out of 4773

Total Ratings

+93.44%

Success Rate

+17.80%

Average Return

Recent Ratings Analysis

CAH

Buy

Jul 23, 2026

Target

$240.00

Current

$234.57

Performance

3.80%

Steven Valiquette rated CAH as Outperform on Jul 23, 2026, setting a price target of 240. Shares have remained stable near 234.57, leaving the 240 target still in play.

VEEV

Buy

Jun 04, 2026

Target

$270.00

Current

$262.40

Performance

46.92%

On Jun 04, 2026, VEEV was given a Outperform rating by Steven Valiquette, with a target price of 270. The stock rallied 46.92% after the rating, narrowing the gap to the target of 270 and validating the bullish stance.

DOCS

Hold

May 14, 2026

Target

$26.00

Current

$25.58

Performance

42.03%

DOCS received a Neutral rating from Steven Valiquette on May 14, 2026, aiming for 26. Investors saw gains of 42.03% that the cautious stance didn’t fully capture.

XRAY

Hold

May 06, 2026

Target

$14.00

Current

$10.46

Performance

-6.10%

On May 06, 2026, Steven Valiquette published a Neutral outlook on XRAY, with a target of 14. Weakness in the stock, now at 10.46, supported the conservative rating.

HSIC

Hold

May 06, 2026

Target

$82.00

Current

$88.36

Performance

21.98%

Steven Valiquette on May 06, 2026 assigned HSIC a Neutral rating, with a price target of 82. Shares outperformed expectations, climbing 21.98% despite the neutral view.

PHR

Buy

Mar 24, 2026

Target

$19.00

Current

$10.31

Performance

-8.60%

On Mar 24, 2026, Steven Valiquette reaffirmed PHR with a Outperform rating, targeting 19. Shares slid 8.60% despite the recommendation, highlighting downside risks.

LFMD

Buy

Mar 16, 2026

Target

$8.00

Current

$3.05

Performance

-30.68%

LFMD was rated Outperform by Steven Valiquette on Mar 16, 2026, with a price objective of 8. This case shows how bullish projections can fail, with the stock now below 3.05.

GDRX

Hold

Feb 27, 2026

Target

$4.00

Current

$3.39

Performance

81.28%

On Feb 27, 2026, Steven Valiquette initiated coverage on GDRX with a Neutral rating and target of 4. The Hold stance underestimated the stock’s strength as it gained 81.28%.

NVST

Hold

Feb 10, 2026

Target

$27.00

Current

$25.55

Performance

-15.31%

Steven Valiquette issued a Neutral recommendation for NVST on Feb 10, 2026, price target set at 27. Market action validated the conservative Hold outlook with shares at 25.55.

MCK

Hold

Feb 05, 2026

Target

$885.00

Current

$881.51

Performance

-7.97%

On Feb 05, 2026, MCK was evaluated by Steven Valiquette, who gave a Neutral rating and target of 885. The Hold call avoided chasing into subsequent weakness of 7.97%.

SOLV

Buy

Jan 20, 2026

Target

$100.00

Current

$87.45

Performance

10.75%

Steven Valiquette rated SOLV as Outperform on Jan 20, 2026, setting a price target of 100. The call has proven timely, with shares rising 10.75% toward the price target of 100.

ALGN

Buy

Jan 20, 2026

Target

$200.00

Current

$150.82

Performance

-8.90%

On Jan 20, 2026, ALGN was given a Outperform rating by Steven Valiquette, with a target price of 200. Despite the Buy call, shares fell from 150.82 to 150.82, challenging the optimistic stance.

MDLN

Buy

Jan 12, 2026

Target

$48.00

Current

$32.53

Performance

-23.85%

MDLN received a Outperform rating from Steven Valiquette on Jan 12, 2026, aiming for 48. The rating hasn’t played out as hoped, with the stock trading 23.85% below expectations.

COR

Buy

Nov 06, 2025

Target

$380.00

Current

$321.57

Performance

-10.73%

On Nov 06, 2025, Steven Valiquette published a Outperform outlook on COR, with a target of 380. Market action contradicted the Buy thesis, as shares slipped to 321.57.

WAY

Buy

Oct 30, 2025

Target

$50.00

Current

$23.47

Performance

-36.67%

Steven Valiquette on Oct 30, 2025 assigned WAY a Outperform rating, with a price target of 50. The call has struggled to gain traction, with shares losing 36.67%.

TDOC

Hold

Jul 25, 2025

Target

$10.00

Current

$6.16

Performance

-24.88%

On Jul 25, 2025, Steven Valiquette reaffirmed TDOC with a Neutral rating, targeting 10. The Hold stance reflected market caution that was later justified.

TALK

Buy

Dec 04, 2024

Target

$5.00

Current

$5.25

Performance

45.43%

TALK was rated Outperform by Steven Valiquette on Dec 04, 2024, with a price objective of 5. A bullish response from the market helped close the gap of -0.25 to the target.

HQY

Buy

Dec 04, 2024

Target

$126.00

Current

$96.26

Performance

-6.54%

On Dec 04, 2024, Steven Valiquette initiated coverage on HQY with a Outperform rating and target of 126. The Buy call has yet to be validated as shares remain 29.74 away from the target.

Frequency Asked Questions

Who is Steven Valiquette?

Steven Valiquette is an analyst from Mizuho specializing in the Healthcare sector.

What is Steven Valiquette's success rate?

Steven Valiquette currently has a success rate of +93.44%.

How many ratings has Steven Valiquette issued?

Steven Valiquette has issued 30 stock ratings so far.

What is the average return of Steven Valiquette's calls?

Their stock ratings have generated an average return of +17.80%.

What is Steven Valiquette's ranking?

Steven Valiquette is ranked #1500 out of 4773 analysts.

What types of ratings does Steven Valiquette give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Steven Valiquette?

You can follow Steven Valiquette by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Steven Valiquette?

Their latest rating was a Buy on CAH issued on 2026-07-23.